Nayak D, Lv D, Yuan Y, Zhang P, Hu W, Nayak A
Nat Commun. 2024; 15(1):2743.
PMID: 38548768
PMC: 10979003.
DOI: 10.1038/s41467-024-46922-4.
Jedram O, Maphanao P, Karnchanapandh K, Mahalapbutr P, Thanan R, Sakonsinsiri C
ACS Omega. 2024; 9(1):1278-1286.
PMID: 38222611
PMC: 10785084.
DOI: 10.1021/acsomega.3c07556.
Ailawadhi S, Parrondo R, Dutta N, Han B, Ciccio G, Cherukuri Y
Cancers (Basel). 2023; 15(2).
PMID: 36672426
PMC: 9857228.
DOI: 10.3390/cancers15020477.
Doroshenko A, Tomkova S, Kozar T, Stroffekova K
Front Pharmacol. 2022; 13:991554.
PMID: 36267274
PMC: 9577225.
DOI: 10.3389/fphar.2022.991554.
Osterlund E, Hirmiz N, Pemberton J, Nougarede A, Liu Q, Leber B
Sci Adv. 2022; 8(16):eabm7375.
PMID: 35442739
PMC: 9020777.
DOI: 10.1126/sciadv.abm7375.
Strategies to Reduce the On-Target Platelet Toxicity of Bcl-x Inhibitors: PROTACs, SNIPERs and Prodrug-Based Approaches.
Negi A, Voisin-Chiret A
Chembiochem. 2022; 23(12):e202100689.
PMID: 35263486
PMC: 9311450.
DOI: 10.1002/cbic.202100689.
ROR2 increases the chemoresistance of melanoma by regulating p53 and Bcl2-family proteins via ERK hyperactivation.
Castro M, Barbero G, Mascolo P, Ramos R, Quezada M, Lopez-Bergami P
Cell Mol Biol Lett. 2022; 27(1):23.
PMID: 35260073
PMC: 8903712.
DOI: 10.1186/s11658-022-00327-7.
BH3-mimetics: recent developments in cancer therapy.
Townsend P, Kozhevnikova M, Cexus O, Zamyatnin Jr A, Soond S
J Exp Clin Cancer Res. 2021; 40(1):355.
PMID: 34753495
PMC: 8576916.
DOI: 10.1186/s13046-021-02157-5.
B Cell Lymphoma 2: A Potential Therapeutic Target for Cancer Therapy.
Alam M, Ali S, Mohammad T, Hasan G, Yadav D, Hassan M
Int J Mol Sci. 2021; 22(19).
PMID: 34638779
PMC: 8509036.
DOI: 10.3390/ijms221910442.
Precision treatment exploration of breast cancer based on heterogeneity analysis of lncRNAs at the single-cell level.
Zhang Y, Zhang D, Meng Q, Liu Z, Xie H, Liu L
BMC Cancer. 2021; 21(1):918.
PMID: 34388989
PMC: 8361656.
DOI: 10.1186/s12885-021-08617-7.
Computational Modeling as a Tool to Investigate PPI: From Drug Design to Tissue Engineering.
Perez J, Perez R, Perez A
Front Mol Biosci. 2021; 8:681617.
PMID: 34095231
PMC: 8173110.
DOI: 10.3389/fmolb.2021.681617.
KIM-1 mediates fatty acid uptake by renal tubular cells to promote progressive diabetic kidney disease.
Mori Y, Ajay A, Chang J, Mou S, Zhao H, Kishi S
Cell Metab. 2021; 33(5):1042-1061.e7.
PMID: 33951465
PMC: 8132466.
DOI: 10.1016/j.cmet.2021.04.004.
Biomimetic Approaches to the Synthesis of Natural Disesquiterpenoids: An Update.
Caprioglio D, Salamone S, Pollastro F, Minassi A
Plants (Basel). 2021; 10(4).
PMID: 33916090
PMC: 8065479.
DOI: 10.3390/plants10040677.
Synergistic Effects of TW-37 and ABT-263 on Renal Cell Carcinoma Cells.
Yu R, Lu Y, Yu R, Xie J, Zhou S
Cancer Manag Res. 2021; 13:953-963.
PMID: 33568941
PMC: 7868206.
DOI: 10.2147/CMAR.S265788.
Targeting Protein Neddylation to Inactivate Cullin-RING Ligases by Gossypol: A Lucky Hit or a New Start?.
Yu Q, Sun Y
Drug Des Devel Ther. 2021; 15:1-8.
PMID: 33442232
PMC: 7797302.
DOI: 10.2147/DDDT.S286373.
BCL2L10 Is Overexpressed in Melanoma Downstream of STAT3 and Promotes Cisplatin and ABT-737 Resistance.
Quezada M, Picco M, Villanueva M, Castro M, Barbero G, Fernandez N
Cancers (Basel). 2021; 13(1).
PMID: 33396645
PMC: 7795116.
DOI: 10.3390/cancers13010078.
Synthesis and structure-activity relationship of coumarins as potent Mcl-1 inhibitors for cancer treatment.
Xia Y, Wang J, Li S, Liu Y, Gonzalez F, Wang P
Bioorg Med Chem. 2020; 29:115851.
PMID: 33218896
PMC: 7855844.
DOI: 10.1016/j.bmc.2020.115851.
Small-molecule active pharmaceutical ingredients of approved cancer therapeutics inhibit human aspartate/asparagine-β-hydroxylase.
Brewitz L, Tumber A, Zhang X, Schofield C
Bioorg Med Chem. 2020; 28(20):115675.
PMID: 33069066
PMC: 7588595.
DOI: 10.1016/j.bmc.2020.115675.
AT101 [(-)-Gossypol] Selectively Inhibits MCL1 and Sensitizes Carcinoma to BH3 Mimetics by Inducing and Stabilizing NOXA.
Mallick D, Eastman A
Cancers (Basel). 2020; 12(8).
PMID: 32824203
PMC: 7464284.
DOI: 10.3390/cancers12082298.
Antitumor effect of TW-37, a BH3 mimetic in human oral cancer.
Ahn C, Lee W, Jung Y, Shin J, Hong K, Choi S
Lab Anim Res. 2020; 35:27.
PMID: 32257914
PMC: 7081630.
DOI: 10.1186/s42826-019-0028-7.